Savara has received U.S. and Canadian patents for its AeroVanc powdered, inhaled formulation of the antibiotic vancomycin hydrochloride, which combats treatment-resistant lung infections in cystic fibrosis (CF) patients. AeroVanc addresses the growing challenge of the methicillin-resistant Staphylococcus aureus (MRSA) bacteria, Savara said in a press release. The patents from the United States Patent and Trademark…
News
Scientists at Boston University’s Center for Regenerative Medicine have made two stem cell discoveries that could help doctors treat cystic fibrosis (CF) without having to resort to transplants. They prevented stem cells from creating cells for a lot of organs at once and producing only the lung cells they need…
Fifteen non-profit groups in seven countries will receive Cystic Fibrosis Circle of Care project grants totaling nearly $1 million this year, the program’s sponsor, Vertex Pharmaceuticals, announced. The grants, now in their third year, go to medical, academic, patient, and community organizations serving the cystic fibrosis (CF) community. Since the program started in…
A more light weight and mobile vest for people with cystic fibrosis or related diseases who need help with airway clearance is now available for use at home or while traveling through its developer, Hill-Rom, the company announced. The system is based on a mobile vest created by a CF patient. A number of…
Researchers from Massachusetts General Hospital and Harvard Medical School have developed a primary palliative care framework to improve cystic fibrosis (CF) patient care and reduce the symptom burden. This model aims to integrate palliative care with standard CF therapies to promote a positive effect on the long-term quality…
Multi-drug-resistant nontuberculous mycobacteria (NTM) can be found in the gastric juice and tubes that are used to feed some cystic fibrosis (CF) patients, research shows. Tube feeding, known as gastrostomy, involves surgeons inserting a tube through the abdominal wall and into the stomach. Gastrostomy can also be used to drain…
Yet another consequence of lung infections with the bacterium Pseudomonas (P.) aeruginosa in cystic fibrosis (CF) patients has been discovered, researchers report. But this time, it may be to the disadvantage of the microbe. Another type of bacteria, normally only present on teeth, can hijack Pseudomonas factors to prevent its…
A new test able to screen for the risk for inherited conditions such as cystic fibrosis (CF) will be jointly commercialized by SYNLAB and Counsyl, two companies dedicated to the development of genetic screening tests. Under a new agreement signed by the two companies, SYNLAB will offer Counsyl’s…
A way of treating drug-resistant bacterial infections in people with cystic fibrosis (CF) that draws on preventing the bacteria from taking hold in the lung — through the use of histidine kinase inhibitors — was the focus of a recent review. The study, by scientists at Wageningen University & Research, Netherlands, is titled “…
A large Irish study found that patients with cystic fibrosis (CF) who have lung infections with both Aspergillus fumigatus (AF) and Pseudomonas aeruginosa (PA) have a poor prognosis, compared to those with persistent PA infections. Co-colonization with these two microorganisms may contribute to the damage of the airways of these…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.